Introduction {#s1}
============

Adequate management of existential distress is essential to psychosocial care in cancer, yet it has only recently been focused in specialized interventions and distress measures [@pone.0059417-Kissane1]--[@pone.0059417-Nissim1]. Existential distress in cancer patients may arise from the impact of multiple existential challenges raised by cancer diagnosis and treatment, which include fear of death and dying and the threat to fundamental human needs for autonomy, self-worth, relatedness, and meaning [@pone.0059417-Rodin1], [@pone.0059417-Chochinov1]. Evidence grows showing that existential distress is a relevant factor influencing psychological well-being in cancer, although heterogeneous conceptualizations have been used [@pone.0059417-LeMay1]. However, few studies have examined the occurrence of existential distress and predicting factors, mostly limited to small samples of patients with advanced illness.

The concept of demoralization provides a profound base for assessment of existential distress in cancer patients not covered by standard diagnostic approaches. Clarke and Kissane [@pone.0059417-Clarke1] define demoralization as an affective state of loss of meaning and hopelessness, with cognitions of helplessness and personal failure, subjective incompetence, and social alienation. Research has repeatedly applied this concept to severe medical illness, emphasizing that demoralization is essentially characterized by an entrapped feeling that "nothing can be done" and a subsequent loss of hope and meaning, while the two core symptoms of major depression, anhedonia and loss of interest, are typically not present [@pone.0059417-deFigueiredo1]--[@pone.0059417-Connor1]. Factor analytic studies support the conceptual and clinical separation of demoralization and major depression in cancer patients [@pone.0059417-Clarke2], [@pone.0059417-Jacobsen1]. Validated measures have shown good psychometric properties and capacity to differentiate demoralized from depressed patients, despite considerable overlap [@pone.0059417-Kissane3], [@pone.0059417-Grassi1].

Previous studies examining predictors of demoralization have found positive associations with the number of physical problems and negative associations with social support and partnership [@pone.0059417-Clarke2], [@pone.0059417-Vehling1]--[@pone.0059417-Grassi2]. Results regarding age, gender, and treatment phase are inconsistent, however. Positive [@pone.0059417-Vehling1], negative [@pone.0059417-Clarke2], [@pone.0059417-Mehnert1], [@pone.0059417-Cockram1], or no associations with age [@pone.0059417-Grassi1], [@pone.0059417-Lee1] were found. Most studies found no gender differences [@pone.0059417-Clarke2], [@pone.0059417-Grassi1], [@pone.0059417-Vehling1], [@pone.0059417-Lee1], except for one study [@pone.0059417-Mehnert1]. In addition, while it is widely accepted that the existential burden among patients with advanced cancer is linked to existential distress [@pone.0059417-LeMay1], [@pone.0059417-Chochinov2], [@pone.0059417-Kissane4], palliative vs. curative treatment phase or advanced vs. early disease stage were not associated with higher demoralization [@pone.0059417-Grassi1], [@pone.0059417-Vehling1], [@pone.0059417-Lee1], [@pone.0059417-Boscaglia1]. These studies did mostly not control for confounding variables and none of them considered interaction effects. More complex underlying associations may however account for absent effects of cancer-related variables [@pone.0059417-Scheier1]. Hence, combined with the pattern of previous results, a three-way interaction of age, gender, and treatment phase may contribute to inconsistent associations between these factors and demoralization in previous studies.

The aims of the present study were to (1) assess the occurrence of demoralization in a large sample of cancer patients with mixed tumor sites, and (2) examine the impact of the age×gender×treatment phase three-way interaction on demoralization, controlling for the number of physical problems and positive social support. We (3) examined if the impact of these predictors on demoralization was independent of the overlap between demoralization and depression.

We hypothesized a significant positive effect of physical problems and a significant negative effect of positive social support on demoralization (a). Further, a significant age×gender×treatment phase interaction under control of physical problems and social support was assumed (b). We finally hypothesized a significant effect of the number of physical problems, positive social support, and the age×gender×treatment phase interaction on demoralization when depression was controlled (c).

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

The study was approved by the local medical association research ethics committee (Ethik-Kommission der Ärztekammer Hamburg). Written informed consent was obtained from all participating patients.

Participants {#s2b}
------------

A subsample of a representative multicenter epidemiologic study on the prevalence of comorbid psychiatric disorders [@pone.0059417-Mehnert2] involving patients recruited from the major study center in Hamburg, Germany was analyzed. Patients with malignant tumors aged 18 to 75 years were consecutively recruited from acute care hospitals, outpatient treatment facilities and rehabilitation centers between March 2009 and October 2010 by trained research assistants. Exclusion criteria were severe physical and cognitive impairment and insufficient proficiency in German to provide informed consent and complete questionnaires. Patients were informed about the study and provided questionnaires and stamped return envelopes after written informed consent had been obtained. Basic demographic data was recorded from non-participants. Non-participants were slightly older than participants (M = 60.5, SD = 10.6 vs. M = 57.7, SD = 12.1; P\<.001), but did not differ in gender (P = .10). Most frequent reasons to decline participation were lack of interest (62%) and physical or psychological symptom burden (16%). Patient flow is shown in [figure 1](#pone-0059417-g001){ref-type="fig"}.

![Recruitment of study sample.](pone.0059417.g001){#pone-0059417-g001}

Measures {#s2c}
--------

Sociodemographic data including age, gender, marital status, and education were assessed by a standardized self-report questionnaire. Medical data including tumor entity, date of first diagnosis, UICC-stage, and curative vs. palliative treatment phase were obtained from medical charts and professional treatment reports. Classification of treatment phase was based on the current intention of oncologic treatment as evaluated by the attending physician. This evaluation was based on tumor stage (presence and extent of metastases), disease progression (remission, stable disease, or progressive disease), and current and past oncologic treatment modalities (type and dose of chemotherapy, radiotherapy, surgery, and other therapies).

*Demoralization* within the past two weeks was assessed by the German version of the Demoralization Scale (DS) [@pone.0059417-Kissane3], [@pone.0059417-Mehnert1]. Total scores may range from 0 to 96. A cutoff score of 36 was used to indicate high demoralization and a cutoff score of 30 was used to indicate moderate demoralization [@pone.0059417-Kissane3], [@pone.0059417-Vehling1]. The *number of physical problems* was measured by the physical problems list of the NCCN Distress Thermometer [@pone.0059417-Mehnert3], assessing the presence of 21 common physical symptoms in cancer patients. *Social support* was measured by the positive support subscale of the Illness-Specific Social Support Scale Short Version-8 (ISSS-8) [@pone.0059417-Revenson1], [@pone.0059417-Ullrich1]. Total scores may range from 0 to 16. *Depression* within the past two weeks was assessed using the DSM-IV-based depression module of the Patient Health Questionnaire (PHQ-9) [@pone.0059417-Lowe1]. Scores may range from 0 to 27. A cutoff score of 10 was used to indicate moderate depression and a cutoff score of 15 was used to indicate high depression.

Statistical Analysis {#s2d}
--------------------

Descriptive statistics including means, standard deviations, and frequencies of demoralization were calculated across sample characteristics. Group differences and bivariate associations were calculated using ANOVA, t-test, χ^2^-test, and Pearson correlation coefficient. Hierarchical moderated multiple regression analysis was used to analyze our predictor and interaction hypotheses concerning demoralization. Applying the Aiken and West [@pone.0059417-Aiken1] procedure for probing three-way interactions, predictor variables were entered into the regression equation in three subsequent steps. In the first step (model 1), number of physical problems, social support, age, gender, and treatment phase were simultaneously entered, estimating first-order effects of all variables. In the second step (model 2), the two-way-interactions age×gender, age×treatment phase, and gender×treatment phase were entered. The three-way interaction age×gender×treatment phase was entered separately in the third step (model 3). The fourth step included depression as a control variable in order to examine if hypothesized predictors showed a significant effect over and above the effect of depression on demoralization (model 4).

For regression analyses, unstandardized regression coefficients (b-values) are reported only, as standardized coefficients of interaction terms are not interpretable [@pone.0059417-Aiken1], [@pone.0059417-Fox1]. Continuous predictor variables were standardized and categorical variables were contrast coded prior to analyses. Thus, in presence of a significant interaction effect, the simple effect of each predictor variable involved in the interaction term is the effect of that variable at the average level (i.e. zero) of the other variables [@pone.0059417-Aiken1], [@pone.0059417-Whisman1]. Interaction terms were calculated by multiplication of respective variables.

The following analyses were carried out to further analyze the possible three-way interaction: simple slopes of the relationship between age and demoralization were calculated for all gender×treatment phase subgroups (i.e., female/palliative treatment, male/palliative treatment, female/curative treatment, and male/curative treatment) [@pone.0059417-Aiken1]. Further, differences between each pair of simple slopes were tested for significance using the Dawson and Richter [@pone.0059417-Dawson1] slope difference test. Power calculation according to the Dawson and Richter equation showed that our sample size was sufficient to detect a slope difference of small effect size (i.e., Δb = 0.1) with power of β = 0.8. Error variances were homogenous across gender×treatment phase subgroups, with error variance ratios ranging between 1:1.01 and 1:1.36 [@pone.0059417-Alexander1], [@pone.0059417-Aguinis1]. All p-values are two-sided, and all analyses were performed using R version 2.14.1 and PASW Statistics version 18.0.

Results {#s3}
=======

Sample Characteristics and Frequency of Demoralization {#s3a}
------------------------------------------------------

[Table 1](#pone-0059417-t001){ref-type="table"} shows demographic and medical sample characteristics and demoralization means, standard deviations, and frequencies across subgroups. Of the total sample, 15.3% were seriously demoralized (DS≥36) and 8.4% were moderately demoralized (DS≥30). The mean demoralization score was 20.8 (SD = 13.9, range = 0--69).

10.1371/journal.pone.0059417.t001

###### Sample characteristics and descriptive statistics for demoralization.

![](pone.0059417.t001){#pone-0059417-t001-1}

                                                   Sample      Demoralization Mean          Demoralization Frequency (DS≥36)                                        
  --------------------------------------------- ------------- --------------------- ------ ---------------------------------- --------------- ----- --------------- -------------
  Total sample                                       750               100           20.8                 13.9                                 115       15.3       
  *Gender*                                                                                                                     \<.001 (.028)                         .001 (.123)
  Female                                             394              52.5           23.1                 14.7                                 77        19.5       
  Male                                               356              47.5           18.4                 12.6                                 38        10.7       
  *Age, mean (SD)*                               57.7 (12.2)                                         \<.001 (.034)                                   \<.001 (.167)  
  18--39                                             65                8.7           25.4                 16.2                                 18        27.7       
  40--59                                             313              41.7           22.9                 14.8                                 61        19.5       
  60--75                                             372              49.6           18.4                 12.2                                 36         9.7       
  *Marital status*                                                                                                              .001 (.024)                          .10 (.092)
  Married/partnership                                587              79.6           20.0                 13.7                                 85        14.5       
  Single                                             67                9.1           25.6                 15.2                                 14        20.9       
  Separated/divorced                                 54                7.3           24.9                 13.5                                 11        20.4       
  Widowed                                            29                3.9           16.7                 8.8                                   1         3.4       
  *Education*                                                                                                                   .11 (.008)                           .20 (.079)
  Elementary school (8--9 years)                     174              23.4           19.0                 12.4                                 21        12.1       
  Junior high school (10 years)                      241              32.4           20.9                 14.9                                 35        14.5       
  High school (13 years)                             113              15.2           23.1                 15.1                                 24        21.2       
  University                                         216              29.0           21.1                 13.3                                 35        16.2       
  *Tumor site*                                                                                                                 \<.001 (.035)                         .015 (.152)
  Breast                                             228              30.4           21.2                 14.7                                 38        16.7       
  Prostate                                           198              26.4           17.0                 12.0                                 15         7.6       
  Hematologic                                        59                7.9           22.4                 13.5                                 12        20.3       
  Gynecologic                                        58                7.7           25.1                 14.4                                 13        22.4       
  Colorectal                                         40                5.3           19.6                 11.5                                  4        10.0       
  Lung                                               29                3.9           23.9                 13.6                                  6        20.7       
  Head and Neck                                      27                3.6           22.7                 15.6                                  7        25.9       
  Other                                              111              14.8           23.1                 14.7                                 20        18.0       
  *Treatment phase*                                                                                                             .032 (.006)                          .27 (.041)
  Curative                                           584              77.9           20.3                 13.7                                 85        14.6       
  Palliative                                         166              22.1           22.9                 14.4                                 30        18.1       
  *UICC tumor stage*                                                                                                            .30 (.002)                           .52 (.024)
  0-II                                               419              60.9           20.7                 13.9                                 64        15.3       
  III--IV                                            269              39.1           21.8                 14.1                                 46        17.1       
  *Months since initial diagnosis, mean (SD)*    27.5 (47.7)                                                                                                        
  *Type of disease*                                                                                                             .001 (.019)                          .056 (.088)
  Initial diagnosis                                  577              76.9           19.9                 13.6                                 79        13.7       
  Recurrence                                         117              15.6           25.2                 14.5                                 26        22.2       
  Second tumor                                       56                7.5           21.1                 14.3                                 10        17.9       
  *Treatment setting*                                                                                                           .23 (.002)                           .042 (.076)
  Inpatient                                          354              47.2           20.2                 13.3                                 44        12.4       
  Outpatient                                         396              52.8           21.4                 14.4                                 71        17.9       
  *No. of physical problems, mean (SD)*           5.4 (3.8)                                                                                                         
  *Social support, mean (SD)*                    13.8 (2.7)                                                                                                         
  *Depression, mean (SD)*                         5.9 (4.6)                                          \<.001 (.252)                                   \<.001 (.427)  
  Low                                                589              79.3           17.3                 11.3                                 45         7.6       
  Moderate (PHQ≥10)                                  111              14.9           31.8                 14.5                                 43        38.7       
  High (PHQ≥15)                                      43                5.8           39.6                 14.3                                 25        58.1       

Abbreviations: DS, demoralization; d, t-test effect size; η^2^, ANOVA effect size; φ, χ^2^-test effect size; SD, standard deviation; PHQ, Patient Health Questionnaire.

\[t-test/ANOVA\], ^b^\[χ^2^-test\].

Predictors of Demoralization {#s3b}
----------------------------

Bivariate correlations with demoralization and intercorrelations among predictors are reported in [table 2](#pone-0059417-t002){ref-type="table"}. Predictor intercorrelations were small to moderate and variance inflation factors were below 1.8 for all coefficients, showing no evidence of multicollinearity.

10.1371/journal.pone.0059417.t002

###### Bivariate correlations with demoralization and intercorrelations among predictors.

![](pone.0059417.t002){#pone-0059417-t002-2}

  Predictors                                         Demoralization   No. of physical problems   Social support    Age     Gender[\#](#nt103){ref-type="table-fn"}   Treatment phase[§](#nt104){ref-type="table-fn"}                                        
  ------------------------------------------------- ---------------- -------------------------- ---------------- -------- ----------------------------------------- ------------------------------------------------- ------ -------- ------ -------- ----- ------
  No. of physical problems                                .49                  \<.001                  --           --                                                                                                                                      
  Social support                                          −.28                 \<.001                 −.12         .002                      --                                            --                                                               
  Age                                                     −.16                 \<.001                 −.20        \<.001                     .06                                           .10                          --      --                          
  Gender[\#](#nt103){ref-type="table-fn"}                 −.17                 \<.001                 −.17        \<.001                     .01                                           .71                         .32    \<.001    --      --          
  Treatment phase[§](#nt104){ref-type="table-fn"}         .08                   .032                  .16         \<.001                    −.02                                           .54                         .04     .29     −.02    .62     --     --
  Depression                                              .61                  \<.001                 .62         \<.001                    −.11                                          .002                         −.27   \<.001   −.24   \<.001   .11   .003

−1  =  female, +1  =  male.

−1  =  curative, +1  =  palliative.

Results of moderated regression analyses are shown in [table 3](#pone-0059417-t003){ref-type="table"}; model 3 shows coefficients resulting after inclusion of all interaction terms. A higher number of physical problems (b = 6.10, P\<.001) and lower social support (b = −3.17, P\<.001) were significant predictors of demoralization (hypothesis a). Analyses further showed a small but significant three-way interaction between age, gender, and treatment phase (b = 1.30, P = .018, ΔR^2^ = .006) (hypothesis b).

10.1371/journal.pone.0059417.t003

###### Hierarchical regression analyses of predictors and interaction effects contributing to demoralization.

![](pone.0059417.t003){#pone-0059417-t003-3}

                                                               Demoralization                                                                              
  ----------------------------------------------------------- ---------------- ------ -------- ------- ----- -------- ------- ----- -------- ------- ----- --------
  No. of physical problems[\*](#nt106){ref-type="table-fn"}         6.15        .45    \<.001   6.19    .45   \<.001   6.10    .45   \<.001   2.35    .49   \<.001
  Social support[\*](#nt106){ref-type="table-fn"}                  −3.08        .43    \<.001   −3.16   .43   \<.001   −3.17   .43   \<.001   −2.81   .39   \<.001
  *Simple effects*                                                                                                                                         
  Age[\*](#nt106){ref-type="table-fn"}                              −.46        .46     .32     −.30    .55    .59     −.33    .55    .54      .40    .50    .42
  Gender[\#](#nt107){ref-type="table-fn"}                          −1.09        .46     .017    −1.64   .53    .002    −1.71   .53    .001    −1.03   .48    .031
  Treatment phase[§](#nt108){ref-type="table-fn"}                   .06         .52     .91      .12    .53    .83     −.09    .53    .87     −.13    .48    .78
  *Two-way interactions*                                                                                                                                   
  Age × gender                                                                                  1.11    .46    .015    1.81    .54    .001    1.30    .49    .009
  Age × treatment phase                                                                          .15    .55    .78      .23    .55    .67      .12    .50    .81
  Gender × treatment phase                                                                      −.95    .53    .072    −1.05   .53    .048    −.99    .48    .039
  *Three-way interaction*                                                                                                                                  
  Age × gender × treatment phase                                                                                       1.30    .55    .018     .85    .49    .086
  *Control variable*                                                                                                                                       
  Depression[\*](#nt106){ref-type="table-fn"}                                                                                                 6.62    .50   \<.001
  *Explained variance*                                                                                                                                     
  ΔR^2^                                                                         .008    .006    .131                                                       
  R^2^                                                              .295        .303    .309    .440                                                       
  Adjusted R^2^                                                     .290        .296    .300    .432                                                       

Abbreviations: b, regression coefficient (unstandardized); SE, standard error of b; ΔR^2^, change in R^2^ compared to previous model.

Standardized predictors.

−1 = female, +1 = male.

−1 = curative, +1 = palliative.

The plot of the three-way interaction effect in [figure 2](#pone-0059417-g002){ref-type="fig"} shows simple slopes of relationships between age and demoralization for all gender×treatment phase subgroups, controlling for physical problems and social support. Simple slope analyses showed a significant negative relationship between age and demoralization for women receiving palliative treatment, and a significant positive relationship for men receiving palliative treatment. There was no significant association with age for both men and women receiving curative treatment.

![Three-way interaction of age, gender, and treatment phase on demoralization.\
Simple slopes of the relationship between age and demoralization for gender×treatment phase subgroups. Analyses were controlled for the number of physical problems and social support, i.e. simple slopes were calculated for sample means of these variables. Abbreviations: b, regression coefficient of simple slope (unstandardized).](pone.0059417.g002){#pone-0059417-g002}

As shown in [table 4](#pone-0059417-t004){ref-type="table"}, there was a significant difference between the simple slopes of the regression lines for men receiving palliative treatment and women receiving palliative treatment (t = 3.41, P = .001).

10.1371/journal.pone.0059417.t004

###### Test of differences between simple slopes of the relationship between age and demoralization.

![](pone.0059417.t004){#pone-0059417-t004-4}

                              \(1\)   \(2\)   \(3\)   \(4\)                     
  -------------------------- ------- ------- ------- ------- ------ ------ ---- ----
  \(1\) Female, palliative     --      --                                       
  \(2\) Female, curative      −1.47    .14     --      --                       
  \(3\) Male, curative        1.43     .15    0.02     .98     --     --        
  \(4\) Male, palliative      3.41    .001    1.97    .049    1.89   .060   --   --

Abbreviations: b, regression coefficient of simple slope (unstandardized); SE, standard error of b; t, t-value calculated by Dawson & Richter slope difference test.

Examining gender differences, simple slope analyses further showed that demoralization was higher in women for patients receiving palliative treatment aged 61 or younger (b~61~ = 1.92, P = .40). There were no gender differences among patients receiving curative treatment or patients older than 61. Palliative treatment phase was associated with higher demoralization in women and with lower demoralization in men for patients aged 51 or younger (women: b~51~ = 1.98, P = .045; men: b~51~ = −1.55, P = .049). The small additional significant simple effect of gender on demoralization ([table 3](#pone-0059417-t003){ref-type="table"}, model 3) indicates higher demoralization in women than in men at (hypothetical) average sample levels of age and treatment phase.

Model 4 finally shows regression results after including depression as a control variable ([table 3](#pone-0059417-t003){ref-type="table"}). When depression was controlled, b-coefficients were lower for all significant predictors. All b-coefficients were still significant, except for the interaction (P = .086). Thus hypothesis (c) received only partial support.

Discussion {#s4}
==========

We found moderate to high demoralization in 24% of our sample including cancer patients with mixed tumor sites receiving curative and palliative oncologic treatment. Demoralization was associated with a higher number of physical problems, less positive social support, and a three-way interaction of age, gender, and curative vs. palliative treatment phase in a controlled model. Effects were not statistically explainable by the overlap between demoralization and depression. The interaction identified different relationships between age and demoralization depending on the combination of gender and treatment phase. Demoralization decreased with age only among women receiving palliative treatment and increased with age only among men receiving palliative treatment. Demoralization was not significantly related to age in curative patients.

Previous studies have, to our knowledge, rarely examined interactions of demographic and medical variables on demoralization or related outcomes in cancer. Our results are yet comparable to previous literature to the extent to which studies have examined simple effects of age, gender, or treatment phase in homogeneous samples, controlled for respective intercorrelations, and controlled for predictors that covary with these variables. Our results are consistent with the limited effect of curative vs. palliative treatment on demoralization in our earlier study [@pone.0059417-Vehling1]. The higher percentage of men receiving palliative treatment (19% vs. 10%) may have contributed to the positive effect of age in that study. Similarly, Jones *et al.* [@pone.0059417-Jones1] found no effect of advanced tumor stage on hopelessness in a mixed sample, and no associations between age and demoralization were found in samples including a high rate of early-stage patients [@pone.0059417-Grassi1], [@pone.0059417-Lee1]. More generally, our results are consistent with reviews concluding a negative effect of age on distress in breast and gynecological cancer [@pone.0059417-Mosher1], [@pone.0059417-ArdenClose1], and missing [@pone.0059417-Mehnert4], [@pone.0059417-Rosenfeld1] or positive [@pone.0059417-Nelson1] age effects in prostate cancer. Interestingly, Miller *et al.* [@pone.0059417-Miller1] found no gender differences in patients with metastasized lung and gastrointestinal cancer. Our findings support the idea that the higher age of patients with these tumors is a possible explanation to this result. In line with our findings, a recent prospective study showed an age×gender interaction indicating improvement in distress among younger men and older women, but not among older men and younger women [@pone.0059417-GieseDavis1].

Despite the limited overall impact of palliative treatment on existential distress, our results indicate that related existential challenges moderate the impact of age- and gender-specific vulnerability factors on demoralization in cancer. Younger age has been linked to a number of vulnerability factors, including cancer as an "off-time" event, greater interference with role functioning, and less coping experience from negative life events [@pone.0059417-Blank1]. Higher distress in female patients has been related to gender roles and socialization effects as most relevant causal vulnerability factors [@pone.0059417-Hagedoorn1], [@pone.0059417-Kuehner1]. Our findings suggest that these factors and their interaction may become more relevant in face of a high existential burden, which, given our analyses controlled for the number of physical problems, is not entirely captured by physical impairment and its consequences. But what is the nature of these existential challenges and how can age- and gender-related differences in responses to them be explained?

Rodin and Zimmerman [@pone.0059417-Rodin1] suggest that an existential challenge essential to psychological well-being for patients with advanced cancer is the capacity to tolerate the "double awareness" of realizing death and yet maintaining a sense of meaning from sources of personal value. While this challenge may generally raise more difficulties for younger patients, our results indicate that related coping responses may diverge across gender. For younger women, awareness of a limited prognosis may more often imply an inability to shift focus toward new sources of hope and meaning, increasing the risk for demoralization. On the other hand, younger men may more often distract awareness from the reality of a foreshortened life and focus on sustaining a sense of normality and control, causing them to report lower levels of demoralization. This idea is consistent with the more frequent use of ruminative coping in response to negative events in women [@pone.0059417-NolenHoeksema1]. Among younger women with breast cancer, worries about family members were further found to be a central source of distress [@pone.0059417-Siegel1], and to impede coping with the existential dialectic of hope and hopelessness in the terminally ill [@pone.0059417-Sachs1]. On the other hand, male gender role expectations of stoicism and self-reliance have been suggested to explain distracting coping responses in men [@pone.0059417-Tamres1]. Evidence concerning gender differences in coping is nevertheless limited, and information is especially missing about emotion regulation in men [@pone.0059417-NolenHoeksema1]. Similarly, there is a lack of studies investigating psychosocial adjustment to existential challenges among younger men with advanced cancer.

We further found that gender differences decreased with higher age. This is consistent with an age-related increase of protective existential factors in both genders: spiritual well-being and attachment security were shown to mediate the decrease of depression with age [@pone.0059417-Lo1], and negative associations were found between personal meaning, sense of coherence, spiritual well-being, or attachment security and demoralization [@pone.0059417-Boscaglia1], [@pone.0059417-Vehling2], hopelessness [@pone.0059417-Rodin2], and loss of dignity [@pone.0059417-Chochinov2].

The rate of 24% reporting at least moderate demoralization in the present study underscores the relevance of demoralization within the spectrum of distress related to cancer. Associations between independent variables and demoralization were not simply accounted for by depression as an explanatory third variable, supporting the idea that demoralization covers a distinct domain of existential distress experienced by cancer patients. Longitudinal studies however need to confirm that prolonged and untreated existential distress is an important factor in development of depression and the desire for hastened death [@pone.0059417-Rodin2], [@pone.0059417-MonforteRoyo1], while first results point toward this direction [@pone.0059417-Brothers1]. The strong negative effect of positive social support in our study further strengthens the good response of demoralization to supportive psychosocial interventions drawn from clinical experience [@pone.0059417-Kissane2], [@pone.0059417-Jacobsen2]. The association with positive support was stronger for demoralization compared to depression, strengthening the rationale of interventions directly focusing on existential concerns.

Limitations of our study include the number of non-participants due to high physical and psychological symptom burden, which might have led to an underestimation of demoralization in our sample, especially in older patients, as non-participants were somewhat older than participants. The 65% participation rate is however satisfactory in the cancer context. Second, the age distribution of our sample was skewed toward higher age, as it is mostly the case in cancer patient samples. Our model did however not violate regression assumptions, as homoscedasticity of regression residuals across the age continuum was confirmed and no evidence of extreme outliers was found, supporting the generalizability of our data. However inclusion of patients older than 75 years would have provided a fuller picture. Another limitation was the unequal distribution of patients receiving curative and palliative treatment. Although the assumption of homogeneous error variances across subgroups was met, this reduced the power of our moderator analyses. The variance explained by the interaction was small, but within the range usually expected for three-way interactions [@pone.0059417-Whisman1]. Finally, the simple dichotomy of curative vs. palliative treatment phase does not reflect the progress in cancer treatment toward gradual transition from curative to palliative care. The related decline of strict criteria to distinguish curative from palliative treatment phase involves a subjective evaluation of treatment phase by the attending physician. It may further explain the 8% of participating patients we had to exclude from analyses due to unclear treatment phase. The dichotomy does further not attend to possible differences in existential challenges between patients with early-stage and advanced cancer receiving treatment with curative intention according to their treating physician [@pone.0059417-Ryan1]. However, we chose to examine the psychological impact of physician-rated treatment intention rather than tumor stage because this may provide a closer approach to practical changes in communication about prognosis and treatment goals relevant to the perceived existential threat in the context of progressive disease.

In conclusion, the present study shows that existential distress in terms of demoralization is (a) frequent in cancer and (b) depends on a complex interaction of demographic and medical patient characteristics. One explanation to the latter is that existential challenges related to palliative treatment bring age- and gender-specific vulnerability and protective factors of existential distress into sharper relief. Moreover, these results provide a new perspective on the limited or inconsistent simple effects of palliative treatment, age, and gender on existential distress in previous research; future studies should consider that the effects of these variables depend on their sample-based distribution, which is to a large extent determined by the tumor site of the patients studied. Further improvement of knowledge about subgroup resources and vulnerabilities in the context of existential threat would provide valuable input for interventions focusing on the individual experience of existential challenges among cancer patients.
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